PRECISION BIOSCIENCES INC
NASDAQ: DTIL (Precision BioSciences, Inc.)
Kemas kini terakhir: 22 jam lalu7.17
-0.07 (-0.97%)
| Penutupan Terdahulu | 7.24 |
| Jumlah Dagangan | 191,403 |
| Harga / Pendapatan (P/E Ke hadapan) | 11.78 |
| Harga / Jualan (P/S) | 3.24 |
| Harga / Buku (P/B) | 4.37 |
| Julat 52 Minggu |
| Margin Keuntungan | -42.99% |
| Margin Operasi (TTM) | -76,248.27% |
| EPS Cair (TTM) | -2.87 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -99.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 60.30% |
| Nisbah Semasa (MRQ) | 6.62 |
| Aliran Tunai Operasi (OCF TTM) | -58.52 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 6.86 M |
| Pulangan Atas Aset (ROA TTM) | -17.83% |
| Pulangan Atas Ekuiti (ROE TTM) | -50.81% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Precision BioSciences, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.83 |
|
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 10.94% |
| % Dimiliki oleh Institusi | 42.73% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Empery Asset Management, Lp | 30 Jun 2026 | 776,093 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |